New selective inhibitors of cap dependent proteins: synthesis, delivery and chaos (Q84205): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Changed an Item) |
||
| Property / beneficiary | |||
| Property / beneficiary: University of Warsaw / rank | |||
Normal rank | |||
Revision as of 18:56, 9 June 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | New selective inhibitors of cap dependent proteins: synthesis, delivery and chaos |
Project in Poland financed by DG Regio |
Statements
4,500,000.0 zloty
0 references
4,500,000.0 zloty
0 references
100.0 percent
0 references
1 June 2017
0 references
30 November 2021
0 references
UNIWERSYTET WARSZAWSKI
0 references
The project aims at the design, synthesis, and evaluation of novel mRNA 5’ cap analogs as selective inhibitors of three major cap-related proteins: the eukaryotic translation initiation factor 4E (eIF4E) and the two decapping enzymes (DcpS and Dcp2). The proteins were selected due to their key roles in mRNA function and an already-confirmed status as molecular targets for cancer and neuromuscular diseases. To achieve the goal, we propose a comprehensive approach encompassing 1) generation of novel cap derivatives, either by traditional chemical synthesis or by combinatorial approach based on in situ click chemistry, 2) ideas for novel molecular probes and screening approaches specifically tailored for each of the proteins, 3) in-depth evaluation of the found inhibitors using biophysical, biochemical, and structural methods to understand their mechanism of action at the molecular level, 4) application of several cell-delivery strategies to demonstrate the biological potential in vivo. (Polish)
0 references
The project approaches at the design, synthesis, and evaluation of novel mRNA 5’ caps as selective inhibitors of three major cage-related proteins:the eucartic translation ambiguity 4E (eIF4E) and the two decepping enzymes (DcpS and Dcp2).The proteins former due to their formal status in mRNA and neuromusculcular diseases.To achieve the good, in a comprehensive approach encompassing 1. (English)
0 references
Identifiers
POIR.04.04.00-00-20A2/16
0 references